TSVT Stock Price, 2seventy bio, Inc. Quote, Chart

Market Summary

USD4.28-0.35

Market Closed

-7.56%

TSVT Alerts

1 major insider buys recently.

TSVT Stock Price

View Fullscreen

TSVT RSI Chart

TSVT Valuation

Market Cap

237.6M

Price/Earnings (Trailing)

-1.09

Price/Sales (Trailing)

2.37

EV/EBITDA

-0.78

Price/Free Cashflow

-1.31

TSVT Price/Sales (Trailing)

TSVT Profitability

EBT Margin

-216.73%

Return on Equity

-85.22%

Return on Assets

-38.48%

Free Cashflow Yield

-76.09%

TSVT Fundamentals

TSVT Revenue

Revenue (TTM)

100.4M

Rev. Growth (Yr)

-80.98%

Rev. Growth (Qtr)

-11.22%

TSVT Earnings

Earnings (TTM)

-217.6M

Earnings Growth (Yr)

-145.53%

Earnings Growth (Qtr)

20.68%

Breaking Down TSVT Revenue

Last 7 days

-4.7%

Last 30 days

-9.7%

Last 90 days

49.8%

Trailing 12 Months

-45.3%

How does TSVT drawdown profile look like?

TSVT Financial Health

Current Ratio

3.98

TSVT Investor Care

Shares Dilution (1Y)

2.23%

Diluted EPS (TTM)

-4.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	124.7M	147.3M	145.9M	100.4M
2022	51.0M	57.2M	51.4M	91.5M
2021	199.7M	151.3M	102.9M	54.5M
2020	0	0	146.2M	248.1M
2019	0	0	0	44.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 2seventy bio, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	eatwell victoria	acquired	-	-	42,500	chief financial officer
Apr 01, 2024	snow jessica	acquired	-	-	31,250	see remarks
Apr 01, 2024	baird william d iii	acquired	-	-	56,250	president and ceo
Mar 26, 2024	casdin capital, llc	bought	203,992	5.0998	40,000	-
Mar 25, 2024	casdin capital, llc	bought	1,673,990	5.0727	330,000	-
Mar 22, 2024	casdin capital, llc	bought	754,069	5.1166	147,377	-
Mar 21, 2024	casdin capital, llc	bought	1,470,990	4.9033	300,000	-
Mar 20, 2024	newton charles w.	acquired	-	-	16,600	-
Jan 08, 2024	baird william d iii	acquired	-	-	91,000	chief operating officer
Jan 08, 2024	leschly nick	acquired	-	-	235,000	president and ceo

Which funds bought or sold TSVT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	27.00	80.00	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-67.44	-10,000	7,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	9,479	115,644	-%
Apr 18, 2024	Diversified Trust Co	sold off	-100	-44,318	-	-%
Apr 17, 2024	BARRETT & COMPANY, INC.	unchanged	-	71.00	353	-%
Apr 15, 2024	PFS Partners, LLC	unchanged	-	122	605	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	107	237,139	384,949	0.01%
Apr 10, 2024	Wedmont Private Capital	new	-	483,808	483,808	0.04%
Apr 09, 2024	Halpern Financial, Inc.	reduced	-39.76	-139	498	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	150	150	-%

Are Funds Buying or Selling TSVT?

Are funds buying TSVT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TSVT

No. of Funds

TSVT Alerts

1 major insider buys recently.

Unveiling 2seventy bio, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	4.99%	2,527,672	SC 13G/A
Feb 13, 2024	vanguard group inc	7.87%	3,985,770	SC 13G/A
Feb 12, 2024	morgan stanley	9.4%	4,748,235	SC 13G
Feb 08, 2024	goldman sachs group inc	8.8%	4,471,192	SC 13G
Feb 01, 2024	millennium management llc	4.7%	2,357,072	SC 13G/A
Jan 26, 2024	blackrock inc.	7.7%	3,911,724	SC 13G/A
Jan 23, 2024	state street corp	1.93%	977,590	SC 13G/A
Nov 09, 2023	wellington management group llp	1.59%	802,967	SC 13G/A
Oct 10, 2023	state street corp	2.12%	1,069,125	SC 13G/A

Recent SEC filings of 2seventy bio, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	8-K	Current Report
Apr 05, 2024	8-K	Current Report
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	3	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	8-K/A	Current Report
Mar 28, 2024	4	Insider Trading

Peers (Alternatives to 2seventy bio, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-0.30%	-28.67%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	8.14%	-4.26%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.4B	-	-13.93%	67.39%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.40%	-0.33%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-6.74%	-16.88%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

2seventy bio, Inc. News

Latest updates

2seventy bio, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	-11.2%	10,684,000	12,034,000	36,048,000	41,621,000	56,177,000	13,408,000	13,482,000	8,429,000	16,035,000	19,257,000	7,328,000	11,901,000	15,167,500	18,434,000	-
Costs and Expenses	-21.5%	70,620,000	90,002,000	84,039,000	93,334,000	83,389,000	81,776,000	90,454,000	99,017,000	84,405,000	84,495,000	95,299,000	104,271,000	-	94,848,000	-
S&GA Expenses	24.6%	16,201,000	13,004,000	19,489,000	20,720,000	18,701,000	19,610,000	17,278,000	23,861,000	24,481,000	22,996,000	21,402,000	24,627,000	-	22,105,000	-
R&D Expenses	-0.2%	51,217,000	51,315,000	59,980,000	68,246,000	60,144,000	58,155,000	64,557,000	65,879,000	50,223,000	61,131,000	63,692,000	77,571,000	-	72,253,000	-
EBITDA Margin	-72.8%	-2.06	-1.19	-1.16	-1.65	-2.65	-5.44	-4.70	-5.38	-5.06	-1.04	-0.71	-0.54	-0.43	-2.11	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	20.7%	-56,822,000	-71,638,000	-42,089,000	-47,021,000	-23,143,000	-67,879,000	-77,420,000	-85,711,000	-60,975,000	-60,001,000	-84,042,000	-87,196,000	-	-72,075,000	-
EBT Margin	-71.9%	-2.17	-1.26	-1.22	-1.73	-2.78	-5.69	-4.97	-5.70	-5.36	-1.17	-0.79	-0.60	-0.48	-2.19	-
Net Income	20.7%	-56,822,000	-71,638,000	-42,089,000	-47,021,000	-23,143,000	-67,879,000	-77,420,000	-85,711,000	-60,976,000	-60,001,000	-84,040,000	-87,196,000	-76,801,000	-72,075,000	-
Net Income Margin	-71.9%	-2.17	-1.26	-1.22	-1.73	-2.78	-5.69	-4.97	-5.70	-5.36	-2.99	-2.12	-0.67	-0.48	-2.19	-
Free Cashflow	-166.9%	-64,708,000	-24,244,000	-36,622,000	-55,179,000	-59,753,000	-74,031,000	-49,125,000	-77,067,000	-58,414,000	-45,974,000	-43,120,000	-71,101,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-11.8%	565	641	706	742	657	709	787	852	760	193	313
Current Assets	-14.2%	238	277	334	390	301	349	384	413	292	25.00	25.00
Cash Equivalents	-16.9%	75.00	90.00	96.00	194	71.00	127	270	271	130	-	-
Net PPE	-4.2%	58.00	61.00	61.00	59.00	56.00	47.00	39.00	35.00	35.00	34.00	144
Goodwill	-	-	-	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00	13.00
Liabilities	-7.3%	310	334	338	341	346	386	408	405	400	251	238
Current Liabilities	-12.1%	60.00	68.00	67.00	77.00	80.00	80.00	99.00	106	98.00	106	76.00
Shareholder's Equity	-16.7%	255	306	367	401	310	323	379	447	360	-	75.00
Retained Earnings	-12.5%	-511	-454	-382	-340	-293	-270	-202	-125	-39.49	-	-
Additional Paid-In Capital	0.7%	767	762	752	744	607	598	585	575	400	-	-
Shares Outstanding	0.0%	51.00	51.00	50.00	50.00	38.00	35.00	38.00	27.00	23.00	23.00	23.00
Float	-	-	-	508	-	-	-	497	613	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-196.5%	-63,637	-21,463	-32,712	-49,088	-47,593	-60,613	-46,452	-73,482	-57,260	-43,350	-41,495	-64,750	-	-	-
Share Based Compensation	-49.5%	4,953	9,800	7,740	9,666	9,405	12,207	9,689	9,739	14,323	11,229	11,968	17,109	-	-	-
Cashflow From Investing	198.3%	47,890	16,054	-64,881	44,798	-8,500	-82,295	49,799	44,749	1,014	-8,624	-3,625	-6,351	-	-	-
Cashflow From Financing	437.3%	253	-75.00	128	127,084	232	175	-4,277	170,099	186,694	51,974	45,120	71,101	-	-	-

TSVT Income Statement

2023-12-31

Consolidated and Combined Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Collaborative arrangement revenue	$ 71,601	$ 32,358	$ 26,921
Total revenues	100,387	91,496	54,522
Operating expenses:
Research and development	230,758	248,735	252,617
Cost of manufacturing for commercial collaboration	14,819	14,851	9,320
Selling, general and administrative	69,414	79,450	93,506
Share of collaboration loss	0	9,642	10,071
Restructuring expenses	8,614	0	0
Cost of royalty and other revenue	2,099	1,726	2,517
Change in fair value of contingent consideration	235	232	439
Goodwill impairment charge	12,056	0	0
Total operating expenses	337,995	354,636	368,470
Loss from operations	(237,608)	(263,140)	(313,948)
Interest income, net	12,413	2,932	88
Other income, net	7,625	6,055	21,647
Loss before income taxes	(217,570)	(254,153)	(292,213)
Income tax expense	0	0	0
Net loss	$ (217,570)	$ (254,153)	$ (292,213)
Net loss per share - basic (in dollars per share)	$ (4.42)	$ (7.13)	$ (12.44)
Net loss per share - diluted (in dollars per share)	$ (4.42)	$ (7.13)	$ (12.44)
Weighted-average number of common shares used in computing net loss per share - basic	49,276	35,637	23,499
Weighted-average number of common shares used in computing net loss per share - diluted	49,276	35,637	23,499
Other comprehensive loss:
Other comprehensive income (loss), net of tax benefit (expense) of $0.0 million, $0.0 million, and $0.0 million for the years ended December 31, 2023, 2022 and 2021, respectively.	$ 2,673	$ (2,165)	$ (712)
Comprehensive loss	(214,897)	(256,318)	(292,925)
Service revenue
Revenue:
Revenue	24,144	55,489	21,381
Royalty and other revenue
Revenue:
Revenue	$ 4,642	$ 3,649	$ 6,220

TSVT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 74,958	$ 71,032
Marketable securities	142,031	195,238
Prepaid expenses	7,365	13,652
Receivables and other current assets	13,411	20,960
Total current assets	237,765	300,882
Property, plant and equipment, net	58,150	55,735
Marketable securities	4,816	1,414
Intangible assets, net	6,594	7,302
Goodwill	0	12,056
Operating lease right-of-use assets	219,958	240,885
Restricted investments and other non-current assets	38,143	38,391
Total assets	565,426	656,665
Current liabilities:
Accounts payable	6,028	7,208
Accrued expenses and other current liabilities	25,688	54,678
Operating lease liability, current portion	12,660	11,164
Deferred revenue, current portion	15,403	3,000
Collaboration research advancement, current portion	0	3,744
Total current liabilities	59,779	79,794
Deferred revenue, net of current portion	3,918	5,000
Operating lease liability, net of current portion	244,013	259,008
Other non-current liabilities	2,416	2,397
Total liabilities	310,126	346,199
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 shares authorized, 0 shares issued and outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 200,000 shares authorized, 50,632 and 37,928 shares issued and outstanding at December 31, 2023 and December 31, 2022 respectively	5	4
Additional paid-in capital	766,716	606,986
Accumulated other comprehensive loss	(204)	(2,877)
Accumulated deficit	(511,217)	(293,647)
Total stockholders’ equity	255,300	310,466
Total liabilities and stockholders’ equity	$ 565,426	$ 656,665

About 2seventy bio, Inc.

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Nick Leschly
WEBSITE	2seventybio.com
INDUSTRY	Biotechnology
EMPLOYEES	425

2seventy bio, Inc. Frequently Asked Questions

What is the ticker symbol for 2seventy bio, Inc.? What does TSVT stand for in stocks?

TSVT is the stock ticker symbol of 2seventy bio, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 2seventy bio, Inc. (TSVT)?

As of Tue Apr 23 2024, market cap of 2seventy bio, Inc. is 237.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TSVT stock?

You can check TSVT's fair value in chart for subscribers.

What is the fair value of TSVT stock?

You can check TSVT's fair value in chart for subscribers. The fair value of 2seventy bio, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 2seventy bio, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TSVT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 2seventy bio, Inc. a good stock to buy?

The fair value guage provides a quick view whether TSVT is over valued or under valued. Whether 2seventy bio, Inc. is cheap or expensive depends on the assumptions which impact 2seventy bio, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TSVT.

What is 2seventy bio, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, TSVT's PE ratio (Price to Earnings) is -1.09 and Price to Sales (PS) ratio is 2.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TSVT PE ratio will change depending on the future growth rate expectations of investors.